Abstract: An optical structure comprising at least one stack having a central filter (1) and two sandwiching optical elements (2,3) between which the central filter (1) is interposed, wherein the central filter (1) is in a matrix material. The matrix material being doped with at least one doping agent, the central filter (1) and the two optical elements (2,3) on either side thereof being assembled by bonding layers (4a, 4b) of a material based on the same matrix material as that of the central filter, the optical elements (2,3) on either side of the central filter (1) and the bonding layers (4a, 4b) each having a refractive index equal to that of the material of the central filter or only differing from this refractive index within a range of plus or minus 0.05, preferably within a range of plus or minus 0.02.

Abstract: The present invention relates to a compound of the following general formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug for inhibiting ferroptosis.

Abstract: A process for preparing a catalyst material, includes: (a) providing a support material having surface hydroxyl (OH) groups, the support material is ceria (CeO2), zirconia (ZrO2) or a combination, and the support material contains between 0.3 and 2.0 mmol OH groups/g of the support material; (b) reacting the support material with at least one of: (b1) a compound containing at least one alkoxy or phenoxy group bound though its oxygen atom to a metal element from Group 5 (V, Nb, Ta) or Group 6 (Cr, Mo, W); (b2) a compound containing at least one hydrocarbon group bound though a carbon atom to a metal element from Group 5 or 6; (b3) a compound containing at least one hydrocarbon group bound though a carbon atom to a metal element which is copper (Cu); and (c) calcining the product obtained in step (b).

Abstract: The invention concerns a method for calibrating a system for real-time measurement of the activity of a cognitive function of a test subject, the method comprising the successive steps of: acquiring electrical signals representative of a neural activity of a test subject; calculating values of markers of the cognitive function activity; generating a plurality of copies of calculated values of markers and adding noise to the generated copies; and, constructing a classifier by machine learning, based on the calculated marker values and noisy copies, the classifier being suitable for measuring the activity of the cognitive function of the test subject by calculating a probability that an electrical signal representative of the neural activity of the test subject results from a predetermined activity state of the cognitive function of the test subject.

Abstract: The present invention relates to a device (40) for generating a control signal for an electrical system (S), comprising: an analog block (46) connected to the input (42) and to the output (44) of the generation device (40), the analog block (46) comprising an electrical circuit comprising a passive analog component, a measuring component and a generator, a digital block (50) comprising at least one digitally controllable component (70), the passive analog component of the electrical circuit being configured so as to generate the first component of the control signal and the generator of the electrical circuit being configured so as to generate the second component of the control signal, the electrical circuit being configured so as to sum the first and the second component that are generated in order to obtain the control signal.

Abstract: The invention relates to multispecific antibody constructs comprising Fab fragments having mutations at the interface of the CH1 and CL domains, said mutations preventing heavy chain/light chain mispairing.

Abstract: According to one aspect, the invention relates to a device (200) for transporting and controlling light beams comprising a light guide (40) comprising a bundle (50) of uncoupled single-mode optical fibers (Fi), each single-mode optical fiber (Fi) being intended to receive an elementary light beam (B1i) at a proximal end and to emit a light beam (B2i) at a distal end, said bundle of single-mode optical fibers comprising, in operation, a minimum radius of curvature corresponding to a maximum curvature of the bundle of fibers.

Abstract: A phonon parametric oscillator is provided. The phonon parametric oscillator comprises a laser for periodically emitting brief optical pulses (IL), an assembly for generating acoustic pulses (IA) and a medium for coupling the acoustic pulses to an object (O), the assembly for generating acoustic pulses comprising an entrance face, an exit face, a conversion medium for converting the brief optical pulses into acoustic pulses and a propagation medium for propagating said acoustic pulses, the entrance and exit faces being reflective to the acoustic pulses, the propagation medium having a defined thickness, the exit face making contact with the coupling medium. In the phonon parametric oscillator according to the invention, the round-trip time of an acoustic pulse due to reflection from the entrance and exit faces, is equal to the emission period (?) of the laser, so that the reflected acoustic pulse is in phase with the following acoustic pulse.

Abstract: Collimation device for an X-ray detection system, the collimation device comprising: a collimator comprising a substantially planar support made of a material with partial or zero radiotransparency, the support being rotatably movable about an axis of rotation (?) which passes through the support and which is perpendicular to a first face of the support which acts as an X-ray plane of incidence referred to as the main plane of the support (P), the support (D) being provided on the first face with a slit which is completely transparent to X-rays and which is configured to generate an X-ray flow when the collimator is exposed to an X-ray source, the slit extending longitudinally in the main plane of the support along an axis located at a non-zero distance (d) from the axis of rotation (?), the slit extending through the entire thickness of the support.

Abstract: Silicone material obtained by a reaction between:—at least one organopolysiloxane (A) that has a molar mass of less than 70,000 g/mol, preferably less than 50,000 g/mol, and contains siloxyl units I.1 and I.2; and—at least one organic compound (B) carrying at least two carboxylic acid groups and having no unsaturation. Y a ? Z b 1 ? SiO 4 - ( a + b ) 2 ( I ? .1 ) Z c 2 ? SiO 4 - c 2 ( I ? .

Abstract: Organic solid three-dimensional polymeric foams, a process for preparing the same, and use thereof, the foams includes a solid continuous phase and pores, wherein the foams have a pore size ranging from 50 nm to 200 ?m and a volumetric fraction of the solid continuous phase is from 0.1 to 60%, with respect to the total volume of the foams, and a polydispersity index from 1 to 30%, the foams being ordered over a volume of at least 100 pores.

Abstract: A method for monitoring a hadron beam during hadron-therapy treatment of a subject including tumour cells labelled with a radiopharmaceutical product, in which the hadron beam includes a plurality of discrete hadron bursts, the method including the following steps: when a burst impacts on the subject, detecting the prompt gamma generated by the interaction of the hadrons of the burst with the tissues of the subject using a Compton telescope and reconstructing an image of the interaction volume; when no burst impacts on the subject, extracting the position of the tumour cells labelled with the radiopharmaceutical product using the Compton telescope and reconstructing an image of the total volume of the tumour; comparing the image of the interaction volume and the image of the total volume of the tumour so as to locate the measured interaction volume relative to the measured total volume of the tumour.

Abstract: A system to localize a micro-device inside a target body part, including: a micro-device remotely steered and controlled from outside the target body part, a control unit including a memory for storing one ultrasound image of the target body part, one probe being brought in contact with a securing body part of the patient, and at least one tracker connected to the micro-device. The probe and the tracker communicate with ultrasounds, the control unit being thus able to localize, in real time, the tracker within an internal referential defined with regards to the probe, and the control unit displays, on a screen, the ultrasound image and displays, in real time, the localization of the micro-device on the ultrasound image.

Abstract: The present invention is in the field of bioluminescence in biology and/or medicine. In particular, the invention provides imidazopyrazine derivatives, processes for preparation thereof, and their uses as luciferins.

Abstract: A cell of fluidic assembly of microchips on a substrate, including: a base having its upper surface intended to receive the substrate; a body laterally delimiting a fluidic chamber above the substrate; and a cover closing the fluidic chamber from its upper surface, wherein the body comprises first and second nozzles respectively emerging onto opposite first and second lateral edges of the fluidic chamber, each of the first and second nozzles being adapted to injecting and/or sucking in a liquid suspension of microchips into and/or from the fluidic chamber, in a direction parallel to the mean plane of the substrate.

Abstract: A method of performing magnetic resonance imaging of a body includes a) immerging the body in a static and substantially uniform magnetic field; b) exciting nuclear spins inside the body using at least one radio-frequency pulse; c) applying to the body a time-varying magnetic field gradient defining at least one trajectory (ST) in k-space and simultaneously acquiring samples of a magnetic resonance signal so as to perform a pseudo-random sampling (KS) of the k-space; and d) applying a sparsity-promoting nonlinear reconstruction algorithm for reconstructing a magnetic resonance image of the body; wherein, at least in a low-spatial frequency region of the k-space, the distance between any two adjacent points belonging to a same trajectory is lower than 1/FOV, FOV being the size of a field of view of the reconstructed image. A magnetic resonance imaging apparatus for carrying out such a method is also provided.

Abstract: The present invention relates to antisense RNAs targeting PMP22 and able to inhibit from 40% to 60% the expression of PMP22 in the cells and a pharmaceutical composition comprising thereof. The antisense RNAs are preferably siRNA and are preferably provided in the form of nanoparticles. The present invention also relates to the use of these antisense RNAs targeting PMP22 for the treatment of Charcot-Marie-Tooth 1A disease.

Abstract: A method for isolating a mammalian genomic DNA replication origin, the method including: isolating the genomic DNA molecules; identifying 500 bp windows within the DNA molecules; isolating from the genomic DNA molecules the fragments that have a size from 500 pb up 6000 pb; selecting a DNA replication origin that is able, when contained in the DNA of an Eukaryotic cell, to produce nascent DNA, and to initiate DNA replication; and isolating the origin.

Abstract: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, for use as a drug, especially as an antibiotic. The present invention also relates to a pharmaceutical composition comprising said compound of formula (I) and at least one pharmaceutically acceptable excipient. The present invention further concerns a method of preparation of a compound of formula (I?).

Abstract: The present invention relates to an expression cassette allowing expression of a functional LRIT3 protein in mammal eyes; said expression cassette is inserted in an expression vector, preferably an adeno-associated virus (AAV); accordingly, the present invention further relates to a recombinant adeno-associated virus (AAV) vector carrying a nucleic acid sequence encoding a normal LRIT3 gene, or fragment thereof, under the control of regulatory sequences which express the product of the gene in the ocular cells, a pharmaceutically acceptable composition comprising such a recombinant AAV vector and to its use for the treatment of congenital stationary night blindness